英国78430名成年人每日步数与步数强度同新发痴呆症的关联
该研究基于英国生物银行前瞻性人群队列,纳入78430名40至79岁且有有效腕部加速度计数据的成年人,随访中位6.9年,866人发生痴呆。分析显示每日步数与全因痴呆风险呈非线性关联,最佳剂量为9826步(HR 0.49),最低剂量为3826步(HR 0.75);较高强度步行的最佳剂量关联更强。
要点
- 每日步数约9826步时全因痴呆风险最低(HR 0.49,95%CI 0.39-0.62)。
- 每日3826步即可达到最大风险降低幅度的一半(HR 0.75,95%CI 0.67-0.83)。
- 峰值30分钟步频最佳剂量112步/分钟与痴呆风险降低关联最强(HR 0.38)。
核心结论
- 在该队列研究中,较高的步数与较低的全因痴呆风险相关。
- 研究结果提示,每日略低于10000步的步数可能与较低的痴呆风险最佳相关。
- 以较高强度进行的步数与痴呆风险的关联更强。
研究设计与样本
- 英国生物银行前瞻性人群队列研究,时间为2013年2月至2015年12月,随访6.9年,数据分析于2022年5月进行。
- 共纳入103684名合格成年人中的78430名40至79岁且有有效腕部加速度计数据者。
- 通过住院或初级保健记录及死亡登记确定痴呆结局,截至2021年10月。
- 采用样条Cox回归评估剂量反应关联。
主要发现
- 在中位随访6.9年(IQR 6.4-7.5年)期间,78430名成年人中866人发生痴呆。
- 每日步数与痴呆风险呈非线性关联,最佳剂量为9826步(HR 0.49,95%CI 0.39-0.62),最低剂量为3826步(HR 0.75,95%CI 0.67-0.83)。
- 偶然步频最佳剂量为3677步(HR 0.58,95%CI 0.44-0.72)。
- 目的性步频最佳剂量为6315步(HR 0.43,95%CI 0.32-0.58)。
- 峰值30分钟步频最佳剂量为112步/分钟(HR 0.38,95%CI 0.24-0.60)。
关键数值与推荐
- 最佳剂量定义为观察到最大风险降低时的暴露值,每日步数最佳剂量为9826步(HR 0.49,95%CI 0.39-0.62)。
- 最低剂量定义为风险降低幅度为观察到的最大风险降低幅度50%时的暴露值,每日步数最低剂量为3826步(HR 0.75,95%CI 0.67-0.83)。
- 偶然步频最佳剂量为3677步(HR 0.58,95%CI 0.44-0.72)。
- 目的性步频最佳剂量为6315步(HR 0.43,95%CI 0.32-0.58)。
- 峰值30分钟步频最佳剂量为112步/分钟(HR 0.38,95%CI 0.24-0.60)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Step-based recommendations may be appropriate for dementia-prevention guidelines. However, the association of step count and intensity with dementia incidence is unknown. OBJECTIVE: To examine the dose-response association between daily step count and intensity and incidence of all-cause dementia among adults in the UK. DESIGN, SETTING, AND PARTICIPANTS: UK Biobank prospective population-based cohort study (February 2013 to December 2015) with 6.9 years of follow-up (data analysis conducted May 2022). A total of 78 430 of 103 684 eligible adults aged 40 to 79 years with valid wrist accelerometer data were included. Registry-based dementia was ascertained through October 2021. EXPOSURES: Accelerometer-derived daily step count, incidental steps (less than 40 steps per minute), purposeful steps (40 steps per minute or more), and peak 30-minute cadence (ie, mean steps per minute recorded for the 30 highest, not necessarily consecutive, minutes in a day). MAIN OUTCOMES AND MEASURES: Incident dementia (fatal and nonfatal), obtained through linkage with inpatient hospitalization or primary care records or recorded as the underlying or contributory cause of death in death registers. Spline Cox regressions were used to assess dose-response associations. RESULTS: The study monitored 78 430 adults (mean [SD] age, 61.1 [7.9] years; 35 040 [44.7%] male and 43 390 [55.3%] female; 881 [1.1%] were Asian, 641 [0.8%] were Black, 427 [0.5%] were of mixed race, 75 852 [96.7%] were White, and 629 [0.8%] were of another, unspecified race) over a median (IQR) follow-up of 6.9 (6.4-7.5) years, 866 of whom developed dementia (mean [SD] age, 68.3 [5.6] years; 480 [55.4%] male and 386 [54.6%] female; 5 [0.6%] Asian, 6 [0.7%] Black, 4 [0.4%] mixed race, 821 [97.6%] White, and 6 [0.7%] other). Analyses revealed nonlinear associations between daily steps. The optimal dose (ie, exposure value at which the maximum risk reduction was observed) was 9826 steps (hazard ratio [HR], 0.49; 95% CI, 0.39-0.62) and the minimal dose (ie, exposure value at which the risk reduction was 50% of the observed maximum risk reduction) was 3826 steps (HR, 0.75; 95% CI, 0.67-0.83). The incidental cadence optimal dose was 3677 steps (HR, 0.58; 95% CI, 0.44-0.72); purposeful cadence optimal dose was 6315 steps (HR, 0.43; 95% CI, 0.32-0.58); and peak 30-minute cadence optimal dose was 112 steps per minute (HR, 0.38; 95% CI, 0.24-0.60). CONCLUSIONS AND RELEVANCE: In this cohort study, a higher number of steps was associated with lower risk of all-cause dementia. The findings suggest that a dose of just under 10 000 steps per day may be optimally associated with a lower risk of dementia. Steps performed at higher intensity resulted in stronger associations.
引用
- Del Pozo Cruz B, Ahmadi M, Naismith SL, et al. Association of Daily Step Count and Intensity With Incident Dementia in 78 430 Adults Living in the UK. JAMA Neurol. 2022. PMID: 36066874. doi:10.1001/jamaneurol.2022.2672
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。